
Clinical and translational research
Ongoing projects
- A phase IIb double-blind placebo-controlled randomized clinical trial (RCT) to evaluate the therapeutic efficacy of ChAd63-KH vaccine in patients with persistent post kala-azar dermal leishmaniasis (PKDL) in Sudan.
- A phase 4 RCT with immunological endpoints of two different HPV vaccines given as 1,2, or 3 doses in 9-12 year old girls in Tanzania.
- The development of a Controlled Human Infection Model (human challenge study) of Leishmania major in healthy volunteers.
- A multicentre study in East Africa to determine the immune set point after treatment for visceral leishmaniasis using sodium stibogluconate / paromomycin combination therapy.
- Conversion And Neuro-inflammation Disorder Observational (CANDO) study. A study to understand more about the causes of conversion disorder so that new treatments can be developed in the future - Phase II is ongoing.
- Spatial analysis of host-parasite interactions in the skin across the clinical spectrum of cutaneous leishmaniasis in Ethiopia.
- Wellcome Trust Technology Development Fund: Resonant Imaging of Cell Secretion in Real Time.
Completed projects
- LEISH1: a phase 1 First-in-Human study to assess the safety and immunogenicity of a new Leishmania vaccine candidate ChAd63-KH.
- NCRN464: A commercial randomised, double-blind, placebo-controlled, phase I/II trial of RNActive®-derived Cancer Vaccine (CV9104) in asymptomatic or minimally symptomatic patients with metastatic castrate-refractory prostate cancer.
- ADON: A commercial 48-week, double-blind, randomised, multi-centre, parallel-group study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute de-myelinating optic neuritis.
- DAPIDAR: A randomised, double blind phase I study to assess the safety, pharmacokinetics and pharmacodynamics of single and 14 days dosing with two anti-HIV vaginal microbicide formulations containing either Darunavir, or Dapivirine plus Darunavir.
- RADIUS: Rheumatology clinical trial, sponsored by Merck.
- CV-9104-004: Oncology clinical trial.
- MABGEL1: phase 1 clinical trial of a triple anti-HIV monoclonal antibody vaginal microbicide.
- MUCOVAC2: Mucosal and systemic HIV vaccine phase 1 clinical trial.
- GENTICEL: Therapeutic HPV vaccine clinical trial, in LSIL, sponsored by Genticel.
- GSK Hand Osteoarthritis: Rheumatology clinical trial, sponsored by GSK.
- IgA Renal: Renal clinical trial, sponsored by Merck.
- NASH: Hepatology clinical trial.
- MATE: A 24 month, multicentre, pilot, randomised controlled trial comparing standard care with individualised treat and extend regimen for treatment of neovascular age-related macular degeneration with aflibercept. Clinical research trial led by Ophthalmology, York Teaching Hospital NHS Foundation Trust.
- Assessing visual cortex in candidates for retinal prosthetics: Collaboration with Ophthalmology, Manchester Royal Eye Hospital and Second Sight Medical Products, Sylmar, CA, USA to study brain structure and function in individuals with age-related macular degeneration before and after implantation with the Argus II retinal prosthesis system.
- Assessing the benefit of ranibizumab treatment for AMD: A basic scientific research study using MRI and routine ophthalmological assessments to measure the benefit of treatment for AMD on cortical changes associated with eye disease.
- Assessing the benefit of ranibizumab treatment for AMD - A follow-up: A follow-up of the above study conducted ~five years later.
- LEISH2a: Assessing the safety and immunogenicity of a new Leishmania vaccine candidate ChAd63-KH (ISRCTN11285604).
- SYNAPTIC: Structural, functional and chemical assessments of the visual pathway in vision loss. A collaboration between York Neuroimaging Centre and Ophthalmology, York Teaching Hospital NHS Foundation Trust.
- CIVIL: Case Investigations of Vision Loss. A collaboration between York Neuroimaging Centre and Ophthalmology, York Teaching Hospital NHS Foundation Trust.
- Visual cortical properties of individuals with congenital loss of cone photoreceptor function: International multicentre study of brain structure and function in individuals with rod achromatopsia, a rare eye condition, led by University of York.
- Assessing the status of visual cortex in patients with macular disease: Collaboration with Ophthalmology, York Teaching Hospital NHS Foundation Trust, funded by Fight for Sight.
- Conversion And Neuro-inflammation Disorder Observational (CANDO) study. A study to understand more about the causes of conversion disorder so that new treatments can be developed in the future - Phase I is completed.